Update on rifampin and rifabutin drug interactions
- PMID: 18277121
- DOI: 10.1097/MAJ.0b013e31814a586a
Update on rifampin and rifabutin drug interactions
Abstract
Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes as well as the P-glycoprotein transport system. Several examples of well-documented clinically significant interactions include warfarin, oral contraceptives, cyclosporine, itraconazole, digoxin, verapamil, nifedipine, simvastatin, midazolam, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Examples of clinically relevant interactions demonstrated by recent reports include everolimus, atorvastatin, rosiglitazone/pioglitazone, celecoxib, clarithromycin, caspofungin, and lorazepam. To avoid a decreased therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, clinicians need to be cognizant of these interactions. Studies and cases of rifampin drug interactions continue to increase rapidly. This review is a timely reminder to clinicians to be vigilant.
Similar articles
-
Rifampin and rifabutin drug interactions: an update.Arch Intern Med. 2002 May 13;162(9):985-92. doi: 10.1001/archinte.162.9.985. Arch Intern Med. 2002. PMID: 11996607 Review.
-
Update on rifampin, rifabutin, and rifapentine drug interactions.Curr Med Res Opin. 2013 Jan;29(1):1-12. doi: 10.1185/03007995.2012.747952. Epub 2012 Nov 30. Curr Med Res Opin. 2013. PMID: 23136913 Review.
-
Update on rifampin drug interactions, III.Arch Intern Med. 1997 Nov 24;157(21):2453-8. Arch Intern Med. 1997. PMID: 9385296 Review.
-
The clinical pharmacokinetics of rifabutin.Clin Infect Dis. 1996 Apr;22 Suppl 1:S15-21; discussion S21-2. Clin Infect Dis. 1996. PMID: 8785251 Review.
-
The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.Clin Pharmacol Ther. 1999 Apr;65(4):428-38. doi: 10.1016/S0009-9236(99)70138-4. Clin Pharmacol Ther. 1999. PMID: 10223781 Clinical Trial.
Cited by
-
Treatment and Toxicity Considerations in Tuberculosis: A Narrative Review.Cureus. 2024 Jun 19;16(6):e62698. doi: 10.7759/cureus.62698. eCollection 2024 Jun. Cureus. 2024. PMID: 39036175 Free PMC article. Review.
-
Characteristics of and treatment outcomes in rifampicin-intolerant patients.IJTLD Open. 2024 Apr 1;1(4):160-165. doi: 10.5588/ijtldopen.23.0466. eCollection 2024 Apr. IJTLD Open. 2024. PMID: 38988405 Free PMC article.
-
Lack of CYP3A4 protein induction despite mRNA induction in primary hepatocytes exposed to rifabutin as a possible explanation for its low interaction risk in vivo.Arch Toxicol. 2024 Aug;98(8):2541-2556. doi: 10.1007/s00204-024-03763-w. Epub 2024 May 7. Arch Toxicol. 2024. PMID: 38713375
-
Advances in Antiretroviral Therapy for Patients with Human Immunodeficiency Virus-Associated Tuberculosis.Viruses. 2024 Mar 23;16(4):494. doi: 10.3390/v16040494. Viruses. 2024. PMID: 38675837 Free PMC article. Review.
-
The differences in drug disposition gene induction by rifampicin and rifabutin are unlikely due to different effects on important pregnane X receptor (NR1I2) splice variants.Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr;397(4):2485-2496. doi: 10.1007/s00210-023-02768-z. Epub 2023 Oct 18. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37851058 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
